Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

1.2K
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

750
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generative artificial intelligence in public health: a framework for governance and systemic integration.

Frontiers in medicine·2026
Same author

Ferroptosis in the tumor immune microenvironment: A double-edged sword in immunotherapy.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Trimethylamine N-Oxide Combined with Phenylacetylglutamine as Potential Biomarkers for Diabetic Kidney Disease.

Diabetes, metabolic syndrome and obesity : targets and therapy·2026
Same author

P2X7R of synovial fibroblasts is a potential therapeutic target associated with refractory rheumatoid arthritis.

Science advances·2026
Same author

Investigating <i>InDels</i> in <i>YAP</i> and <i>TAZ</i> genes and their impact on growth characteristics in goats.

Archives animal breeding·2026
Same author

Application of escitalopram population pharmacokinetic repository: a step to precision dosing.

Translational psychiatry·2026

Related Experiment Video

Updated: Apr 24, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K

Trimethyllysine as a potential biomarker for heart failure.

Yuyan Lei1, Qing Fang2, Qingqi Wu3

  • 1The Second Nanning People's Hospital, The Third Affiliated Hospital of Guangxi Medical University, Nanning, China; Department of Pharmacology, Xiangya School of Pharmaceutical Science, Central South University, Changsha, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|April 22, 2026
PubMed
Summary

Elevated trimethyllysine (TML) levels are linked to heart failure (HF) and may indicate kidney problems in HF patients. This suggests TML could be a useful biomarker for evaluating heart failure.

Keywords:
BiomarkerHeart failureIntestinal microbiotaRenal insufficiencyTrimethyllysine

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K

Related Experiment Videos

Last Updated: Apr 24, 2026

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
10:12

A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay

Published on: August 8, 2013

16.1K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.3K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

7.9K

Area of Science:

  • Biochemistry
  • Cardiology
  • Biomarker Discovery

Background:

  • Trimethyllysine (TML), a methylated amino acid, is involved in carnitine biosynthesis.
  • Previous research suggests a link between TML and cardiovascular disease.

Purpose of the Study:

  • To assess the association between plasma TML and heart failure (HF).
  • To evaluate the potential of TML as a diagnostic biomarker for HF.

Main Methods:

  • Cross-sectional study of 104 participants (65 HF patients, 39 controls).
  • Plasma TML quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  • Statistical analyses included correlation, adjusted odds ratios, and ROC analysis.

Main Results:

  • Plasma TML levels were significantly higher in the HF group.
  • Higher TML levels were independently associated with HF after adjusting for confounders (aOR 5.41, P=0.040).
  • Elevated TML was associated with renal dysfunction in HF patients (OR 32.12, P=0.007).
  • ROC analysis showed an AUC of 0.673 for TML in distinguishing HF.

Conclusions:

  • Elevated plasma TML is independently associated with HF.
  • TML may indicate renal dysfunction in HF patients.
  • TML shows potential as a clinically relevant biomarker for HF evaluation.